Spinal Elements Announces First Clinical Use of the Lucent® 3D Lumbar Interbody System

Spinal Elements, a spine technology company, today announced that the Lucent 3D Lumbar Interbody System has been successfully used in its first clinical cases with Dr. Thomas Noh, Neurosurgeon at Hawaii Pacific Health and Assistant Clinical Professor at the John A. Burns School of Medicine (JABSOM) at the University of Hawaii and Dr. Douglas H. Musser, D.O. at Youngstown Orthopedics Associates in Canfield, Ohio.

The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence. The resulting Lucent 3D implant is comprised of a strut-and-lattice structure with a bone graft chamber access lid designed to allow the surgeon to deliver a large amount of tightly packed graft inside the interbody structure, maximizing the amount of graft material available for fusion. Furthermore, when the access lid to the graft chamber is closed, the lid is designed to maximize surface area in contact with the vertebral endplates. Provided in both straight and curved designs, the interbody device is designed to be placed through an open or MIS posterior approach.

Dr. Noh commented, “The Lucent 3D Interbody is a novel and useful surgical option in my practice. The curved implant was easy to insert and helped to maintain lordosis. Knowing that there is tightly packed graft inside the cage provides additional confidence that a successful fusion will occur.”

Jason Blain, CEO of Spinal Elements, stated, “We are thrilled to share this technology with the surgical community. Lucent 3D’s novel design is meant to address subsidence and the amount of bone graft material available for fusion – two clinical challenges surgeons note exist with other 3D-printed interbody devices. We are pleased to offer additional innovative titanium interbody devices to our expansive and best-in-class product portfolio, adding to our long tradition of innovation in material science, novel designs, and leadership. We truly can answer any need for posterior lumbar fusion and continue to build on our procedural solutions.”

After finishing his first several Lucent 3D cases, Dr. Musser commented, “The design and structure of the Lucent 3D cage have provided a biologic containment area that has enabled me to place more graft material than traditional PLIF and TLIF cages. The Lucent 3D cage also has excellent visualization on both A/P and Lateral views when using fluoroscopy.”

Spinal Elements announced FDA clearance of the Lucent 3D system in April of this year and expects to expand on Lucent 3D’s graft containment concept in other clinical applications.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version